When the worst thing you can say about a company is that its stock
doesn't look very cheap, that's not a bad situation. It is challenging
for me to see substantial undervaluation in Becton Dickison (NYSE: BDX )
these days, even given the company's excellent share in safety
devices, pre-filled syringes, and autoinjectors, and above-average
growth in emerging markets. Although I'd be in no rush to sell, I would
suggest investors keep an eye on the changes under way throughout the
diagnostics industry.
Please read more here:
Becton, Dickinson & Co Poised To Be A Large-Cap Growth Leader
No comments:
Post a Comment